

and can be attributed to the challenging nature of follow-ups of elderly populations. Given that VTE-related complications usually occur within the first 2 y,<sup>1</sup> we estimate that an average follow-up of 1.5 y should be sufficient to identify the impact of most of these complications on QoL.

In our cohort, older VTE patients reported worse QoL than that of the general population of the same age, and the BI was the only independent determinant of QoL. Although our study cannot lead to firm conclusions, the results may be relevant for future research on the influence of VTE-related complications or treatment on the QoL of patients.

## Bibliografía

1. Lubberts B, Pereira NRP, Kabrhel C, Kuter DJ, DiGiovanni CW. What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis. *Thromb Haemost*. 2016;116:417–31.
2. Spencer FA, Gore JM, Lessard D, Emery C, Pacifico L, Reed G, et al. Venous thromboembolism in the elderly a community-based perspective. *Thromb Haemost*. 2008;100:780–8.
3. European Union Comission. The future of health care and care for the elderly: guaranteeing accessibility, quality and financial viability. Brussels: European Union. 2001. Informe Com 2001. 723.final.15-12-200 n.d. [http://europa.eu/rapid/press-release\\_IP-01-1747\\_en.htm](http://europa.eu/rapid/press-release_IP-01-1747_en.htm) [accessed 17.05.17].
4. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol*. 2011;173:676–82.
5. Collin C, Wade D, Davies S, Horne V. The Barthel ADL Index: a reliability study. *Int Disabil Stud*. 1988;10:61–3.
6. Kahn SR, Desmarais S, Ducruet T, Arsenault L, Ginsberg JS. Comparison of the Villalta and Ginsberg clinical scales to diagnose the post-thrombotic syndrome: correlation with patient-reported disease burden and venous valvular reflux. *J Thromb Haemost*. 2006;4:907–8.
7. Ware JE Jr, Kosinski M, Gandek B, Ware JE, Snow KK, Kosinski M, et al. The SF-36 Health Survey: Manual and Interpretation Guide; 1993 [https://www.researchgate.net/publication/247503121\\_SF36\\_Health\\_Survey\\_Manual\\_and\\_Interpretation\\_Guide](https://www.researchgate.net/publication/247503121_SF36_Health_Survey_Manual_and_Interpretation_Guide) [accessed 13.06.16].
8. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual; 1994 <https://www.researchgate.net/publication/>
9. López-García E, Banegas JR, Graciani Pérez-Regadera A, Luis Gutiérrez-Fisac J, Alonso J, Rodríguez-Artalejo F. Valores de referencia de la versión española del Cuestionario de Salud SF-36 en población adulta de más de 60 años. *Med Clin*. 2003;120:568–73.
10. Roman A, Barbera JA, Castillo MJ, Muñoz R, Escribano P. Health-related quality of life in a national cohort of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. *Arch Bronconeumol*. 2013;49:181–8.
11. Lloyd AJ, Dewilde S, Noble S, Reimer E, Lee AYY. What impact does venous thromboembolism and bleeding have on cancer patients' quality of life? *Value Heal*. 2018;21:449–55.
12. Andersen CK, Wittrup-Jensen KU, Lolk A, Andersen K, Kragh-Sørensen P. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. *Health Qual Life Outcomes*. 2004;2:1–7.
13. Kahn SR, Akaberi A, Granton JT, Anderson DR, Wells PS, Rodger MA, et al. Quality of life, dyspnea, and functional exercise capacity following a first episode of pulmonary embolism: results of the ELOPE cohort study. *Am J Med*. 2017;130:990, e9–990.e21.
14. Palacios-Ceña D, Jiménez-García R, Hernández-Barrera V, Alonso-Blanco C, Carrasco-Garrido P, Fernández-de-las-Peñas C. Has the prevalence of disability increased over the past decade (2000–2007) in elderly people? A spanish population-based survey. *J Am Med Dir Assoc*. 2012;13:136–42.
15. Lawrence BJ, Gasson N, Kane R, Bucks RS, Loftus AM. Activities of daily living, depression, and quality of life in Parkinson's disease. *PLoS ONE*. 2014;9:1–5.

Covadonga Gómez-Cuervo\*, Carmen Díaz-Pedroche, Asunción Pérez-Jacoiste Asín, Antonio Lalueza, Raquel Díaz-Simón, Carlos Lumbreiras

Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Spain

\* Corresponding author.

E-mail address: [Covadonga.gomez@salud.madrid.org](mailto:Covadonga.gomez@salud.madrid.org)  
(C. Gómez-Cuervo).

<https://doi.org/10.1016/j.arbres.2019.09.018>

0300-2896/ © 2019 Published by Elsevier España, S.L.U. on behalf of SEPAR.

## Acute Chest Syndrome in Sickle Cell Disease




### Síndrome torácico agudo en la anemia de células falciformes

Dear Editor:

A 24-year-old man with sickle cell disease was admitted to our emergency department due to high fever (39.4 °C) and bilateral pleuritic chest pain that had started 5 days previously. He had been admitted two times in the previous month due to pain crisis and respiratory symptoms. At that time, a chest X-ray showed a consolidation in the left lower lobe, and bacterial pneumonia was diagnosed. Pulmonary auscultation revealed decreased breath sounds over the lower lung fields. Laboratory tests showed mild leukocytosis (white cell count, 14,100/cm<sup>3</sup>) with 64% neutrophils, anemia (hemoglobin level, 7 g/dl), thrombocytosis (790,000 platelets), and elevated C-reactive protein (98 mg/L) and lactate dehydrogenase levels (482 U/L). The patient underwent chest computed tomography (CT) angiography, which demonstrated bilateral pulmonary opacities associated with ground-glass attenuation over the lower lung fields (Fig. 1A) and mild pleural effusion on the right side. Pulmonary thromboembolism was ruled out (Fig. 1B). Two blood culture sets were negative and bronchoscopy was performed; cultures (bacterial and fungal) and GeneXpert results from bronchoalveolar lavage were negative. The patient was diagnosed with acute chest syndrome (ACS) and was treated successfully with blood transfusion, aggressive crystalloid hydration, analgesia, and antibiotic therapy with ampicillin plus sulbactam. His laboratory

test values improved to normal and he was discharged from the hospital 7 days after initial treatment with an oral hydroxyurea prescription. One month after discharge, the patient underwent chest CT, which showed complete resolution of the pulmonary opacities (Fig. 1C). CT also showed characteristic findings of sickle cell disease, such as a small and calcified spleen and H-shaped vertebral bodies secondary to bone infarction of the central endplates (Fig. 1D). The final diagnosis of the condition leading to the patient's hospitalization was ACS.

ACS in patients with sickle cell disease is defined as an acute illness characterized by fever and/or respiratory symptoms (chest pain, dyspnea, or tachypnea), accompanied by the appearance of new pulmonary opacities on imaging examinations.<sup>1,2</sup> This condition is most commonly associated with homozygous sickle cell disease and rarely with heterozygous sickle cell disease.<sup>2</sup> ACS is the leading cause of hospitalization and death among patients with sickle cell disease.<sup>3–5</sup> An exceedingly rare, yet often fatal, complication of ACS is rapid progression to acute respiratory distress syndrome.<sup>2</sup> Three major underlying mechanisms of ACS have been proposed. Infection with an excessive inflammatory response to lung injury is the most frequent cause.<sup>3–5</sup> Infectious agents associated with ACS in children, in decreasing order of frequency, include viruses, mycoplasma, chlamydia, and bacteria (*Staphylococcus aureus*, *Streptococcus pneumoniae*, and others). Fungal infections are uncommon.<sup>4</sup> Another proposed mechanism is that the sickled cells cause vascular occlusion and pulmonary infarction. Lastly, fat embolism syndrome may occur as a result of contents released during



**Fig. 1.** (A) Chest CT image obtained with the lung window setting shows consolidations and ground-glass opacities in both lower lobes. (B) Angio-CT demonstrated no filling defect in the pulmonary arterial system. (C) Chest CT image obtained 1 month after discharge shows complete resolution of the pulmonary opacities. (D) Coronal reconstruction with the bone window setting demonstrates a small and calcified spleen (arrowheads) and H-shaped vertebral bodies with central endplate depressions (arrows).

marrow necrosis, which eventually lodge in the lung and cause pulmonary hypertension and hypoxemia.<sup>6</sup> The most frequent pulmonary imaging finding is consolidation, frequently affecting the lower lobe (right more often than left) in adult patients and the middle lobe in pediatric patients. In addition, pleural effusion is equally common in both age groups.<sup>5</sup> Ground-glass opacities occur less frequently and can have a more homogeneous distribution.<sup>6</sup> Extrapulmonary findings are more prominent in adult patients.<sup>5</sup> The differential diagnosis may be challenging because ACS may clinically and radiologically mimic other conditions, such as pneumonia, pulmonary edema, transfusion-related acute lung injury, pulmonary infarction, and atelectasis.<sup>1,2</sup> To diminish the vicious cycle of sickle cell hemoglobin polymerization and sickling of erythrocytes, the standard treatment is based on hydration and blood transfusion.<sup>1,3,7</sup> The other critical treatment component is antibiotic therapy, as infection is a potential ACS trigger.<sup>1,3,8</sup> The correct identification of ACS using clinical and radiological data and its proper treatment are very important, as the rate of mortality due to this syndrome is estimated to be 10%.<sup>1,3</sup>

## Bibliografía

- Howard J, Hart N, Roberts-Harewood M, Cummins M, Awogbade M, Davis B, et al. Guideline on the management of acute chest syndrome in sickle cell disease. *Br J Haematol.* 2015;169:492–505. <http://dx.doi.org/10.1111/bjh.13348>
- Sossou C, Chika-Nwosuh O, Nnaoma C, Bustillo J, Chohan A, Okundaye E, et al. Misdiagnosis: acute chest syndrome that evolved into acute respiratory distress syndrome in a patient without a documented history of hemoglobinopathy. *Case Rep Med.* 2019;2019:2893056. <http://dx.doi.org/10.1155/2019/2893056>
- Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. *N Engl J Med.* 2000;342:1855–65. <http://dx.doi.org/10.1056/NEJM200006223422502>
- Agarwal HS, Kuttisch JF. Candida albicans induced acute chest syndrome in sickle cell disease. *Pediatr Blood Cancer.* 2019;66:e27727. <http://dx.doi.org/10.1002/pbc.27727>
- Al-Sharydh AM, Alshahrani M, Aldhaferi B, Al-Muhanna AF, Al-Thani H. Radiological patterns in sickle cell disease patients with acute chest syndrome: are there age-related differences? *Saudi J Med Med Sci.* 2019;7:74–9. [http://dx.doi.org/10.4103/sjmm.sjmmms\\_174\\_17](http://dx.doi.org/10.4103/sjmm.sjmmms_174_17)
- Wang MX, Pepin EW, Verma N, Mohammed TL. Manifestations of sickle cell disease on thoracic imaging. *Clin Imaging.* 2018;48:1–6. <http://dx.doi.org/10.1016/j.clinimag.2017.09.001>
- Al-Sawaf O, Köhler P, Eichenauer DA, Böll B, Kochanek M, Shimabukuro-Vornhagen A. Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation. *Ann Hematol.* 2019;98:789–91. <http://dx.doi.org/10.1007/s00277-019-03596-z>
- Claudio AM, Foltanski L, Delay T, Britell A, Duckett A, Weeda ER, et al. Antibiotic use and respiratory pathogens in adults with sickle cell disease and acute chest syndrome. *Ann Pharmacother.* 2019;23. <http://dx.doi.org/10.1177/1060028019846118>, 1060028019846118.

Gabriel Madeira Werberich, Miriam Menna Barreto,  
Edson Marchiori\*

Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

\* Corresponding author.

E-mail address: [edmarchiori@gmail.com](mailto:edmarchiori@gmail.com) (E. Marchiori).